USTR Launches New Section 301 Trade Investigations After Supreme Court Tariff Ruling 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Estée Lauder Sues Jo Malone Over Trademark Dispute Involving Zara 
Amazon Invests $535 Million in Brisbane Robotics Fulfillment Center 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Robinhood Banking Surpasses $1 Billion in Deposits Following Successful Relaunch 
ANZ and Westpac Forecast Two RBA Rate Hikes in March and May 2026 
Boeing Secures $289 Million Smart Bomb Contract With Israel 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Nintendo Stock Surges 10% as Pokémon Pokopia Breaks Sales Records 
Federal Judge Blocks Virginia Social Media Age Verification Law Over First Amendment Concerns 
U.S. Blocks Venezuela From Funding Nicolas Maduro’s Legal Defense in New York Drug Trafficking Case 
Federal Judge Orders Refund of Trump’s Emergency Tariffs, Potentially Returning Up to $182 Billion 
A California jury has awarded $40 million in damages to two women who claimed that long-term use of Johnson & Johnson’s talc-based baby powder caused their ovarian cancer, marking a significant development in the company’s ongoing talc litigation. The verdict was delivered Friday in Los Angeles Superior Court, where jurors concluded that Johnson & Johnson knew for decades about potential cancer risks associated with its baby powder products but failed to warn consumers.
The jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. Both women are California residents who testified that they used Johnson & Johnson baby powder daily after bathing for roughly 40 years. Kent was diagnosed with ovarian cancer in 2014, while Schultz received her diagnosis in 2018. According to trial testimony, both women underwent extensive medical treatment, including major surgeries and numerous rounds of chemotherapy.
During closing arguments, plaintiffs’ attorney Andy Birchfield told jurors that internal company knowledge about cancer risks linked to talc dated back to the 1960s. He argued that Johnson & Johnson deliberately concealed this information to protect sales. The jury ultimately agreed, finding the company liable for failing to warn consumers about potential dangers.
Johnson & Johnson has strongly denied the claims and announced plans to immediately appeal the verdict. Erik Haas, the company’s worldwide vice president of litigation, said the company expects to prevail, arguing that the decision represents an “aberrant adverse verdict.” Defense attorney Allison Brown told jurors that no major U.S. health authority has established a causal link between talc use and ovarian cancer, and that no scientific study proves talc can migrate to reproductive organs.
Johnson & Johnson is currently facing more than 67,000 lawsuits related to its talc products, the majority involving ovarian cancer claims. The company stopped selling talc-based baby powder in the United States in 2020, switching to a cornstarch alternative. Efforts to resolve the litigation through bankruptcy have been rejected multiple times by federal courts, allowing cases to resume.
The verdict underscores the ongoing legal and financial risks Johnson & Johnson faces as talc cancer lawsuits continue to move forward in courts across the country.
